



**25-OH Vitamin D Total  
(Vit D-Direct) Test System**  
Product Code: 9425-300

**1.0 INTRODUCTION**

**Intended Use: The Quantitative Determination of 25-OH Vitamin D Concentration in Human Serum by a Microplate Enzyme Immunoassay, Colorimetric**


**2.0 SUMMARY AND EXPLANATION OF THE TEST**

Vitamin D is a fat soluble secosteroid hormone that is important in the management of calcium and phosphorus concentrations required in the mineralization of bone. Vitamin D has two important forms: cholecalciferol (D<sub>2</sub>) formed in the skin from ultraviolet light and ergocalciferol (D<sub>3</sub>) found in dairy products. However, these forms do not have significant biological activity. The hormonal active form, 1, 25-dihydroxycholecalciferol, is produced through transformations in the liver and kidney. The first step in this conversion is an enzymatic reaction of D<sub>2</sub> or D<sub>3</sub> into 25OH-D<sub>2</sub> or 25OH-D<sub>3</sub>. These 25OH D forms are not freely circulating in blood, but are primarily bound to vitamin D binding protein (VDBP). The high binding affinity of the 25OH D<sub>2</sub> or <sub>3</sub> compared to other derivatives of vitamin D leads to a long half-life in blood and its use as an accurate indicator of Vitamin D status. Vitamin D deficiency has been associated to diseases related to bone damage such as osteomalacia and rickets. Vitamin D can be dietarily supplemented through the use of Vitamin D<sub>2</sub> or vitamin D<sub>3</sub>. The sum of the 25OH D<sub>2</sub> and <sub>3</sub> in serum or plasma is referred to as total 25OH Vitamin D. The accurate measurement of total vitamin D is necessary in monitoring deficient vitamin D patients to achieve the optimum dosage and avoid excessive levels, which are considered toxic.

**3.0 PRINCIPLE**


**Sequential Competitive Method (Type 6):**

The essential reagents required for a solid phase sequential enzyme immunoassay include immobilized antibody, enzyme-antigen conjugate and native antigen. Upon mixing immobilized antibody, and a whole blood sample containing the native antigen, a binding reaction results between the native antigen for a limited number of insolubilized binding sites. The interaction is illustrated by the following equation:



Ab<sub>CW</sub> = Monospecific Immobilized Antibody (Constant Quantity)  
Ag = Native Antigen (Variable Quantity)  
AgAb<sub>CW</sub> = Antigen-Antibody Complex  
k<sub>a</sub> = Rate Constant of Association  
k<sub>a</sub> = Rate Constant of Disassociation  
K = k<sub>a</sub> / k<sub>a</sub> = Equilibrium Constant

After removing any unreacted native antigen by a wash step, the enzyme-conjugated antigen is introduced. The conjugate reacts with sites of the antibody unoccupied by the native antigen.









EnzAg = Enzyme-antigen Conjugate (Constant Quantity)  
EnzAgAb<sub>CW</sub> = Enzyme-antigen Conjugate-Antibody Complex

After a short second incubation, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody-bound fraction is inversely proportional to the native antigen concentration. By utilizing several different calibrators of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

**4.0 REAGENTS**

**Materials Provided:**

- A. Vit D Calibrators – 1ml/vial – Icons A-G**  
Seven (7) vials containing human serum albumin reference calibrators for 25-OH Vitamin D at **approximate\*** concentrations of 0 (A), 5 (B), 10 (C), 25 (D), 46 (E), 85 (F), and 150 (G) in ng/ml. A preservative has been added. Store at 2-8°C.  
\* Exact levels are given on the labels on a lot specific basis  
The calibrators can be expressed in molar concentrations (nM/L) by multiplying by 2.5. For example: 10ng/ml x 2.5 = 25nM/L
- B. Vit D Controls – 1ml/vial – Icons M-N**  
Two (2) vials containing human serum reference controls at concentration established (exact value listed on label). A preservative has been added. Store at 2-8°C.
- C. Vit D Releasing Agent – 12 ml/vial – Icon **  
One (1) vial containing vitamin D binding protein releasing agents. Store at 2-8°C.
- D. Vit D Enzyme Reagent – 12 ml/vial – Icon **  
One (1) vial containing 25-OH Vitamin D<sub>3</sub> (Analog)-horseradish peroxidase (HRP) conjugate in a protein-stabilizing matrix. Store at 2-8°C.
- E. Vit D Antibody Coated Plate – 96 wells – Icon **  
One 96-well microplate coated with < 1.0 µg/ml anti-Vitamin D sheep IgG and packaged in an aluminum bag with a drying agent. Store at 2-8°C.
- F. Wash Solution Concentrate – 20 ml/vial – Icon **  
One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.
- G. Substrate Reagent – 12 ml/vial – Icon **  
One (1) vial containing tetramethylbenzidine (TMB) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in buffer. Store at 2-8°C.
- H. Stop Solution – 8 ml/vial – Icon **  
One (1) vial containing a strong acid (H<sub>2</sub>SO<sub>4</sub>). Store at 2-8°C
- I. Product Insert**

**Note 1:** Do not use reagents beyond the kit expiration date.  
**Note 2:** Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on label.**  
**Note 3:** Above reagents are for a single 96-well microplate.

**4.1 Required But Not Provided:**

1. Pipette capable of delivering 0.025 & 0.100ml (25 & 100µl) with a precision of better than 1.5%.
2. Dispenser(s) for repetitive deliveries of 0.100 & 0.350ml (100 & 350µl) volumes with a precision of better than 1.5%.
3. Microplate washer or a squeeze bottle (optional).
4. Microplate Reader with 450nm and 620nm wavelength absorbance capability.
5. Absorbent Paper for blotting the microplate wells.
6. Plastic wrap or microplate cover for incubation steps.
7. Vacuum aspirator (optional) for wash steps.
8. Timer.
9. Quality control materials.

**5.0 PRECAUTIONS**

**For In Vitro Diagnostic Use  
Not for Internal or External Use in Humans or Animals**

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

**Safe Disposal of kit components must be according to local regulatory and statutory requirements.**

**6.0 SPECIMEN COLLECTION AND PREPARATION**

The specimens shall be blood, serum in type, and taken with the usual precautions in the collection of venipuncture samples. For accurate comparison to establish normal values, a fasting morning serum sample should be obtained. The blood should be collected in a redtop (with or without gel additives) venipuncture tube(s) with no anti-coagulants. Allow the blood to clot for serum samples. Centrifuge the specimen to separate the serum from the cells.

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml (50µl) of the specimen is required.

**7.0 QUALITY CONTROL**

Each laboratory should assay controls at levels in the low, normal and high range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. The individual laboratory should set acceptable assay performance limits. In addition, maximum absorbance should be consistent with past experience. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

**8.0 REAGENT PREPARATION**

- 1. Wash Buffer**  
Dilute contents of wash solution to 1000ml with distilled or deionized water in a suitable storage container. Diluted buffer can be stored at 2-30°C for up to 60 days.

**9.0 TEST PROCEDURE**

*Before proceeding with the assay, bring all reagents, reference calibrators and controls to room temperature (20-27°C).  
\*\*\*Test Procedure should be performed by a skilled individual or trained professional\*\*\**

1. Format the microplates' wells for each serum reference calibrator, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
2. Pipette 0.025 ml (25 µL) of the appropriate extracted 25-OH Vitamin D calibrator, control or specimen into the assigned well.
3. Add 0.100 ml (100 µl) of the 25-OH Vitamin D Releasing Agent to all wells.
4. Mix (**Note 3**) the microplate for 20-30 seconds until homogeneous.
5. Cover and incubate for 30 minutes at room temperature
6. Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.

7. Add 0.350 ml (350 µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
8. Add 0.100 ml (100 µl) of 25-OH Vitamin D Enzyme Reagent to all wells.

**DO NOT SHAKE THE PLATE AFTER ADDITION**

9. Cover and incubate for 30 minutes at room temperature.
10. Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
11. Add 0.350 ml (350 µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
12. Add 0.100 ml (100 µl) of substrate reagent to all wells. **Always add reagents in the same order to minimize reaction time differences between wells.**
- DO NOT SHAKE (MIX) THE PLATE AFTER SUBSTRATE ADDITION**
13. Incubate at room temperature for twenty (20) minutes.
14. Add 0.050 ml (50 µl) of stop solution to each well and gently mix for 15-20 seconds. **Always add reagents in the same order to minimize reaction time differences between wells.**
15. Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm). **The results should be read within fifteen (15) minutes of adding the stop solution.**

- Note 1:** Do not use the working substrate if it looks blue.
- Note 2:** Do not use reagents that are contaminated or have bacteria growth.
- Note 3:** Cycle (start and stop) mixing (4 cycles) for 5-8 seconds/cycle is more efficient than one continuous (20-30 seconds) cycle to achieve homogeneity. A plate mixer can be used to perform the mixing cycles.
- Note 4:** It is extremely important to accurately dispense the correct volume with a calibrated pipette and by adding near the bottom of the microwells at an angle while touching the side of the well.

**10.0 CALCULATION OF RESULTS**

A dose response curve is used to ascertain the concentration of 25-OH Vitamin D in unknown specimens.

1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
2. Plot the absorbance for each duplicate calibrator versus the corresponding 25-OH Vitamin D concentration in ng/ml on linear graph paper (do not average the duplicates of the calibrators before plotting).
3. Connect the points with a best-fit curve.
4. To determine the concentration of 25-OH Vitamin D for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (1.033) intersects the dose response curve at 39.9 ng/ml 25-OH Vitamin D concentration (See Figure 1).


**Note:** Computer data reduction software designed for ELISA assay may also be used for the data reduction. **If such software is utilized, the validation of the software should be ascertained.**

**EXAMPLE 1**

Sample I.D.	Well Number	Abs (A)	Mean Abs (B)	Value (ng/ml)
Cal A	A1	2.559	2.548	0
	B1	2.537		
Cal B	C1	2.041	2.047	5
	D1	2.054		
Cal C	E1	1.848	1.826	10
	F1	1.804		
Cal D	G1	1.286	1.267	25
	H1	1.249		
Cal E	A2	0.934	0.930	46
	B2	0.927		
Cal F	C2	0.654	0.663	85
	D2	0.712		
Cal G	G2	0.511	0.529	150
	H2	0.546		
Pat #1	A3	1.027	1.033	37.5
	A4	1.039		

\*The above data and figure below is for example only. Do not use utilize it for calculating results.

**Figure 1**



Note: Multiply the horizontal values by 2.5 to convert into nM/ml.

**11.0 Q.C. PARAMETERS**

In order for the assay results to be considered valid the following criteria should be met:

1. The absorbance (OD) of calibrator 0 ng/ml should be  $\geq 1.3$ .
2. Four out of six quality control pools should be within the established ranges.

**12.0 RISK ANALYSIS**

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

**12.1 Assay Performance**

1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
5. The addition of substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
6. Plate readers measure vertically. Do not touch the bottom of the wells.
7. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
8. Use components from the same lot. No intermixing of reagents from different batches.
9. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed, is essential. Any deviation from Monobind's IFU may yield inaccurate results.
10. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.

11. It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
12. Risk Analysis, as required by CE Mark IVD Directive 98/79/EC, for this and other devices made by Monobind, can be requested via email from [Monobind@monobind.com](mailto:Monobind@monobind.com).

**12.2 Interpretation**

1. **Measurements and interpretation of results must be performed by a skilled individual or trained professional.**
2. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
3. The reagents for the test system procedure have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays. (Boscatto LM Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin.Chem. 1988:3427-33). For diagnostic purposes, the results from this assay should be used in combination with clinical examination, patient history, and all other clinical findings.
4. For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
5. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, **Monobind shall have no liability.**
6. If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.

**13.0 EXPECTED RANGES OF VALUES**

Based on the published literature the following ranges have been assigned. **These ranges should be used as guidelines only:**

TABLE 1 Expected Values for the Vit D-Direct ELISA	
LEVEL	RANGE (ng/ml)
Very severe vitamin D deficiency	< 5
Severe vitamin D deficiency	5-10
Vitamin D deficiency	10-20
Suboptimal vitamin D provision	20-30
Optimal vitamin D level	30-50
Upper norm	50-70
Overdose, but not toxic	70-150
Vitamin D intoxication	> 150

It is important to keep in mind that establishment of a range of values, which can be expected to be found by a given method for a population of "normal" persons, is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons, each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

**14.0 PERFORMANCE CHARACTERISTICS**

**14.1 Precision**

The within and between assay precision of the 25-OH Vitamin D AccuBind® ELISA Test System were determined by analyses on three different levels of pool control sera. The number, mean value, standard deviation and coefficient of variation for each of these control sera are presented in Table 2 and Table 3.

TABLE 2 Within Assay Precision				
Serum	N	X	$\sigma$	%C.V.
1	20	22.16	1.35	6.10
2	20	34.96	1.44	4.11
3	20	86.09	6.37	7.40

TABLE 3 Between Assay Precision				
Serum	N	X	$\sigma$	%C.V.
1	45	23.88	2.14	8.96
2	45	37.53	3.44	9.17
3	45	87.91	7.1	8.08

**14.2 Sensitivity**

The sensitivity of the Vit-D Direct AccuBind® ELISA test system method was ascertained by determining the variability of the '0' calibrator and using the  $2\sigma$  (95% certainty) statistic to calculate the minimum dose. The test system has an analytical sensitivity of 1.14 ng/ml of Vitamin D concentrations.

**14.3 Accuracy**

The Vit D AccuBind® ELISA Test System was compared with a reference method. A total of 83 biological specimens from low, normal, and high Vit D level populations were used; the values ranged from 9.5ng/ml to 200ng/ml. The least square regression equation and the correlation coefficient were computed for the AccuBind method when compared to the reference method. The data obtained is displayed in Table 4.

Method	Mean	Leas Square Regression Analysis	Correlation Coefficient
Monobind (y)	52.08	$y=1.02(x)+1.33$	0.918
Reference (x)	49.98		

**14.4 Specificity**

The % cross-reactivity of the 25-OH Vitamin D antibody to selected substances was evaluated by adding the interfering substance to a serum matrix at various concentrations. The cross-reactivity was calculated by deriving a ratio between dose of interfering substance to dose of 25-OH Vitamin D needed to displace the same amount of labeled analog.

TABLE 5	
Substance	Cross Reactivity
25-OH Vitamin D2	1.0000
25-OH Vitamin D3	1.0000
Vitamin D2	0.0076
Vitamin D3	0.0039
D2 Active 1,3,25-Hydroxy Vitamin D 2	1.9000
D3 Active 1,3,25-Hydroxy Vitamin D 3	1.1500

**15.0 REFERENCES**

1. Holick, MF. "Vitamin D Status: Measurement, Interpretation and Clinical Application". *Ann Epidemiol.* 2009, 19(2):73 - 78
2. Morris H. A. "Vitamin D: A Hormone for All Seasons-How Much is enough?" *Clin. Biochem. Rev.*, 2005, 26, 21-32.
3. Bikle D. D. "Vitamin D and the skin". *J. Bone Miner. Metab.*, 2010, 28, 117-30.
4. Zerwekh J. E. "Blood biomarkers of vitamin D status". *Am. J. Clin. Nutr.* 2008, 87, 1087S-91S.
5. Moyad M. A. "Vitamin D: a rapid review". *Dermatol Nurs.*, 2009, 21, 25-30.

Effective Date: 2018-Jan-10 Rev. 2 DCO: 1275  
MP9425 Product Code: 9425-300

Size	96(A)	192(B)	480(D)	960(E)	
Reagent (ml)	A)	1ml set	1ml set	2(2ml set)	
	B)	1ml set	1ml set	2(2ml set)	
	C)	1 (12ml)	2 (12ml)	1 (60ml)	2 (60ml)
	D)	1 (12ml)	2 (12ml)	1 (60ml)	2 (60ml)
	E)	1 plate	2 plate	5 plate	10 plate
	F)	1 (20ml)	1 (20ml)	1 (60ml)	2 (60ml)
	G)	1 (12ml)	2 (12ml)	1 (52ml)	2 (52ml)
	H)	1 (8ml)	2 (8ml)	1 (30ml)	2 (30ml)

For Orders and Inquires, please contact



Tel: +1 949.951.2665 Mail: info@monobind.com  
Fax: +1 949.951.3539 Fax: www.monobind.com



CEpartner4U, Esdoornlaan 13  
3951 DBMaarn, The Neatherlands  
www.cepartner4u.eu

Please visit our website to learn more about our products and services.

**Glossary of Symbols  
(EN 980/ISO 15223)**



In Vitro - Diagnostic Medical Device



Temperature Limitation Storage Condition (2-8° C)



Consult Instructions for Use



Catalogue Number



Contains Sufficient Test for Σ



Batch Code



Used By (Expiration Day)



Date of Manufacturer



Manufacturer



Authorized Rep in European Country



European Conformity